Latanoprost/Timolol Eg

Latanoprost, the active ingredient in Latanoprost/Timolol Eg, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It is combined with timolol, a non‑selective beta‑blocker, to lower intra‑ocular pressure in patients with open‑angle glaucoma and ocular hypertension. GNH USA supplies Latanoprost/Timolol Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost/Timolol acts on ocular pressure regulation pathways to manage glaucoma‑related conditions. - Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent conversion to glaucoma. - Secondary open‑angle glaucoma: helps control pressure when other causes are present.

Common Side Effects: - Eye irritation or burning sensation. - Redness of the conjunctiva. - Blurred vision shortly after instillation. - Increased eyelash growth or darkening of the iris.

Serious or Rare Side Effects: - Allergic reaction with swelling or severe eye pain. - Sudden loss of vision. - Systemic beta‑blocker effects such as bradycardia, bronchospasm, or hypotension.

Before using Latanoprost/Timolol, consider the following precautions. - Cardiac assessment: evaluate for bradycardia or heart block. - Respiratory status: avoid in patients with asthma or severe COPD. - Systemic beta‑blocker use: monitor for additive cardiovascular effects. - Ocular conditions: discontinue if severe eye inflammation occurs. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store below 25°C: keep in the original container, protect from light and moisture.

Latanoprost/Timolol may interact with other medications as described below.

Major Interactions (Avoid): - Non‑selective beta‑agonists (e.g., albuterol): may reduce timolol efficacy. - Systemic beta‑blockers: risk of additive bradycardia or hypotension. - Other prostaglandin analogs: increased risk of ocular irritation.

Moderate Interactions (Monitor Closely): - Additional ocular hypotensive agents: monitor intra‑ocular pressure closely. - Topical NSAIDs: may exacerbate corneal irritation. - MAO inhibitors: observe for systemic cardiovascular effects.